Results 191 to 200 of about 31,601 (273)

Response to Infliximab Biosimilar in a Case of Reactive Arthritis: Our Experience

, 2019
A Morey, Bhushan Madke, Adarshlata Singh, Sudhir Singh, Sandeep Kulkarni   +4 more
openalex   +1 more source

SP354PREDICTORS OF RENAL ANEMIA AND EPOETIN BIOSIMILAR THERAPY IN GERMAN HEMODIALYSIS PATIENTS [PDF]

, 2018
Helmut Reichel, Johannes Duttlinger, Danilo Fliser, Gerd Lonnemann   +3 more
openalex   +1 more source

Biosimilars in Malaysia: Regulation and factors associated with confidence to promote their use among hospital pharmacists.

, 2021
Noraisyah Mohd Sani, Adeeba Kamarulzaman, Zoriah Aziz, Noraisyah Mohd Sani, Zoriah Aziz, Zoriah Aziz   +5 more
openalex   +1 more source

Perforating dermatosis in a young female patient receiving adalimumab biosimilar CTP-17 for chronic plaque psoriasis: A case report. [PDF]

SAGE Open Med Case Rep
Lozito A, Baravalle S, Poddine G, Colato C, Carletto A, Fracassi E, Bellinato F, Girolomoni G, Gisondi P.   +8 more
europepmc   +1 more source

Biosimilars [PDF]

Pharmazie in unserer Zeit, 2012
openaire   +1 more source

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS

, 2022
Amal Haujir, Michael Buch Tøstesen, Tarec Christoffer El‐Galaly, Thomas Stauffer Larsen, J. Starklint, CB Poulsen, Pär Josefsson, Erik Clasen‐Linde, Andriette Dessau‐Arp, Michael Roost Clausen, Judit Jørgensen   +10 more
openalex   +1 more source

Biosimilars in Rheumatology: General Issues

, 2015
José M. Serra López-Matencio, Alberto Morell Baladrón   +1 more
openalex   +1 more source

Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.

JAMA Netw Open
Riegler JS, Kesselheim AS, Rome BN.
europepmc   +1 more source

Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes. [PDF]

J Clin Med
Song JH, Kim C, Chung YR, Kim HR.
europepmc   +1 more source

Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration’ by Marshall et al. [PDF]

, 2016
Emery, P, Ghil, J, Vencovský, J, Won Kang, J   +3 more
core   +1 more source